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Edited by Gianni CesareniAbstract Catalytic (SH1) domains of protein tyrosine kinases
(PTKs) demonstrate speciﬁcity for peptide substrates. Whether
SH1 domains diﬀerentiate between tyrosines in a physiological
substrate has not been conﬁrmed. Using puriﬁed proteins, we
studied the ability of Syk, Fyn, and Abl to diﬀerentiate between
tyrosines in a common PTK substrate, c-Cbl. We found that
each kinase produced a distinct pattern of c-Cbl phosphoryla-
tion, which altered the phosphotyrosine-dependent interactions
between c-Cbl and CrkL or phosphatidylinositol 30-kinase (PI3-
K). Our data support the concept that SH1 domains determine
the ﬁnal sites of phosphorylation once PTKs reach their target
proteins.
 2004 Published by Elsevier B.V. on behalf of the Federation of
European Biochemical Societies.
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PTKs are fundamental components of the communication
networks within cells, transmitting signals for growth, diﬀer-
entiation, adhesion, motility, and death. Alteration of PTK
activity can lead to a variety of human diseases, including di-
abetes, cancer, and immune malfunction. The speciﬁcity of
SH1 domains may regulate signaling outcomes involved in
human disease. In multiple endocrine neoplasia type 2B, an
SH1 domain mutation in the substrate-binding pocket of the
RET receptor PTK was found to alter the peptide substrate
preference of the kinase [1]. Clearly, more investigation into
substrate speciﬁcity of SH1 domains is warranted.
The proto-oncogene c-Cbl is a common substrate of PTKs
and acts as both a negative regulator of and a positive eﬀector
for PTKs [2,3]. Tyrosine phosphorylation of c-Cbl occurs
rapidly and robustly in a wide variety of cell types and stim-
ulating conditions [3]. c-Cbl is inducibly phosphorylated by
receptor and non-receptor PTKs, but constitutively phos-
phorylated by oncogenic PTKs and in various cancer cell lines
[3,4]. The carboxy (C)-terminus of c-Cbl contains multiple
tyrosines that receive the bulk of phosphorylation relative to* Corresponding author. Fax: +503-494-3688.
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tyrosines, Y700, Y731, and Y774, allows the SH2 domains of
Crk proteins, Vav, and the p85 subunit of phosphatidylinositol
30-kinase (PI3-K) to bind c-Cbl. More recently, it has been
shown that phosphorylation of Y700, Y731, and Y774 is
necessary for the c-Cbl–CIN85 interaction, which mediates
endocytosis and downregulation of the epidermal growth
factor (EGF) and hepatocyte growth factor (c-Met) receptors
[8–10].
The fact that the C-terminus of c-Cbl is the major site of
phosphorylation in vivo suggests that either there are three-
dimensional constraints that minimize phosphorylation up-
stream or that PTKs have an intrinsic ability to discriminate
between the 22 tyrosines of c-Cbl. Within the C-terminus,
Y700, Y731, and Y774 are heavily phosphorylated [5,6]. It has
been posited that non-receptor PTKs phosphorylate these sites
indiscriminately [3], suggesting a lack of selectivity for indi-
vidual tyrosine motifs. In contrast, studies using peptide sub-
strates have revealed that catalytic (SH1) domains of PTKs are
capable of speciﬁcity [11]. It is unclear, however, whether the
selectivity observed with peptides also applies to physiological
substrates.
We used the protein c-Cbl to determine whether SH1 do-
mains of PTKs are able to discriminate between individual
tyrosines of a physiological substrate. c-Cbl is an ideal sub-
strate because it is a common target for PTKs, it is a regulator
of PTK signaling, and some in vivo sites of phosphorylation
have been mapped. Using puriﬁed proteins, we show that the
SH1 domains of Syk, Fyn, and Abl have diﬀerent preferences
for tyrosines within c-Cbl. Our data suggest that SH1 domains
can provide an additional level of speciﬁcity in PTK signaling.2. Materials and methods
2.1. In vitro kinase assays
The GST-Cbl proteins were expressed in Escherichia coli and puri-
ﬁed over glutathione sepharose beads (Pharmacia). The fusion proteins
were washed once in 0.5 M LiCl, twice in NP40 lysis buﬀer (1% NP40,
20 mM Tris, pH 8.0, 150 mM NaCl, 10% glycerol, 1 mM EDTA, 1
mM PMSF, 10 lg/ml Aprotinin, and 1 mM Na3VO4), and twice in
kinase buﬀer (see below). Bead-bound fusion proteins were resus-
pended in kinase buﬀer. All kinase buﬀers included 20 mM Tris, pH
7.5, 50 mM NaCl, and 1 mM DTT. Syk also required 20 mM MgCl2
and 5 mM MnCl2. Fyn also required 10 mM MgCl2 and 10 mM
MnCl2. Abl also required 10 mM MgCl2. Preliminary kinase assaysation of European Biochemical Societies.
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phosphorylation of substrate. Each kinase was used in excess to avoid
limiting the ﬁnal level of substrate phosphorylation. The reactions were
carried out in 200 lM ATP for 1 h at room temperature. With the
exception of Abl, the kinases were provided by N. Lydon (Kinetix
Pharmaceuticals Inc.) as puriﬁed GST-SH1 fusions. The Abl SH1
domain was generated as previously described [12].
2.2. Gel overlay assays
Products of the in vitro kinase assays described above were separated
by 10% SDS–PAGE and transferred to polyvinylidene diﬂuoride
membrane (PVDF Immobilon), (Millipore). The membrane was dried
at room temperature 2 h – overnight and rehydrated by submersion in
methanol and rinsing in water. The membrane was then rocked for 6–7
h at room temperature in a 10% non-fat milk – TBST (Tris buﬀered
saline+ 0.05% Tween 20) solution, washed three times (10 min each) in
TBST at room temperature, rocked overnight at 4 C in 2 lg/ml (CrkL-
SH2 and p85 N+C-SH2) or 4 lg/ml (p85 N-SH2) of overlay protein in
binding buﬀer (25 mMNaPO4, pH 7.2, 150 mMNaCl, 2.5 mM EDTA,
pH 8.0, 20 mM NaF, 1 mM Na3VO4, 1 mM DTT, 0.1% Tween 20, 1%
non-fat milk), and washed ﬁve times (10 min each) in TBST at room
temperature. Bound overlay protein was detected with either anti-Flag
or anti-p85 antibodies and developed with Enhanced Chemilumines-
cence (Pierce) using a Roche Lumi-Imager. Quantiﬁcation of signal
intensity was accomplished with Roche LumiAnalyst software.
2.3. Immunoblotting
For the overlays, Flag-CrkL SH2 was detected with anti-Flag (Sig-
ma, F3165). Both p85 N-SH2 and N+C-SH2 were detected with anti-
p85 N-SH2 (Upstate Biotechnology, 05-217). PVDF membranes were
stripped in 100 mM b-mercaptoethanol, 2% SDS, and 62.5 mM Tris–
HCl for 40 min at 65 C between immunoblots. Anti-c-Cbl (C15) and
anti-GST (sc-138) were purchased from Santa Cruz Biotechnology.
Anti-phosphotyrosine (4G10) was used as described [12]. Anti-mouse
or rabbit IgG-HRP conjugate was purchased from Promega and used
with Supersignal Chemiluminescent Substrate from Pierce to develop
all immunoblots except 4G10. Anti-mouse IgG-AP conjugate was
purchased from Promega and used with BCIP/NBT Color Develop-
ment Substrate (Promega) to develop 4G10 immunoblots.2.4. Plasmids
The GST-fusion constructs of Cbl were created by subcloning frag-
ments of c-Cbl cDNA into pGEX bacterial expression vectors. NT-Cbl
includes amino acids 1–220. RF-Cbl includes amino acids 144–450. PR-
Cbl includes amino acids 451–541. CT-Cbl includes amino acids 542–
906. The CrkL and p85 constructs were also expressed from pGEX
vectors, but were cleaved from the GST tag with Factor Xa. The CrkL-
SH2 was subcloned as previously described [13] and modiﬁed by the
addition of a C-terminal Flag tag. The pGEX-p85-SH2 constructs were
provided by T. Roberts (Dana Farber Cancer Institute).3. Results
3.1. SH1 domains of PTKs exhibit distinct preferences for
tyrosines within c-Cbl
In order to determine whether SH1 domains can discrimi-
nate between tyrosines of a c-Cbl, we subjected puriﬁed GST-
fusion domains of c-Cbl to phosphorylation in vitro by the
puriﬁed SH1 domains of Syk, Fyn, and Abl. Fig. 1A illustrates
the structure of c-Cbl and maps the regions that were ex-
pressed as GST-fusion proteins. With the exception of one
tyrosine, Y141, shared between NT-Cbl and RF-Cbl, each
GST-fusion domain of c-Cbl contains non-overlapping tyro-
sines. In addition, every fusion protein contains one or more
tyrosines, also noted in Fig. 1A. Full-length c-Cbl was not used
in our studies because it was not possible to generate the
protein with suﬃcient purity.
As shown in Fig. 1B–D and summarized in Table 1, all ki-
nases tested readily phosphorylated the carboxy-terminus of c-Cbl (CT-Cbl), which includes the SH2-recognition sites Y700,
Y731, and Y774. In agreement with data showing that the C-
terminus of c-Cbl is the major site of tyrosine phosphorylation
in vivo [5–7], we observed that CT-Cbl was the preferred
substrate relative to other regions of c-Cbl. The fact that the in
vitro phosphorylation patterns mimic c-Cbl phosphorylation
in vivo suggests that the GST-Cbl fusion proteins fold into
native conformations.
The 68 kDa GST-CT-Cbl protein migrates as a doublet in
10% polyacrylamide gels (uppermost bands in Figs. 1–5). GST-
RF-Cbl also migrates as a doublet (Fig. 1). We microsequenced
the larger of the two GST-CT-Cbl bands (data not shown) and
conﬁrmed the identity of GST-CT-Cbl. The microsequencing
results revealed that the bacterial Hsp70 protein was also
present. While copuriﬁcation of Hsp70 with GST alone or the
other GST-fusion proteins was not evaluated, other investiga-
tors have reported that copuriﬁcation of chaperone proteins,
such as GroEL, is problem encountered when purifying GST-
fusion proteins from E. coli [14]. Also seen in Figs. 1–5 are
smaller forms of the GST-fusion proteins, from bacterial ly-
sates, which copurify with the full-length proteins and migrate
as a smear ahead of the full-length proteins. The smaller forms
suggest some level of degradation and explain the presence of
doublet bands for GST-CT-Cbl and GST-RF-Cbl.
The SH1 domain of Abl only phosphorylated CT-Cbl
(Fig. 1D). In contrast, Fyn phosphorylated RF-Cbl and CT-
Cbl (Fig. 1C), while Syk phosphorylated all of the c-Cbl regions
(Fig. 1B). In the case of PR1-Cbl, Syk phosphorylates tyrosine
455 as it is the only tyrosine present in PR1-Cbl. Phosphory-
lation of tyrosine 455 was conﬁrmed by testing the tyrosine to
phenylalanine mutant version of PR1-Cbl, in which there was
no phosphorylation detectable (data not shown). Phosphory-
lation of the GST-Cbl substrates was independent of GST, as
indicated by the failure of GST to be detected by phosphoty-
rosine immunoblotting (Fig. 1B–D). The diﬀerential phos-
phorylation of c-Cbl supports the concept that PTKs achieve
some of their substrate speciﬁcity through their SH1 domains.
Because the Y700, Y731, and Y774 residues of c-Cbl have
been reported to be the primary sites of phosphorylation of c-
Cbl in vivo, we set out to determine whether SH1 domains of
PTKs could discriminate between these individual tyrosines.
Again, using in vitro kinase assays with puriﬁed proteins, we
compared the phosphotyrosine levels of wild-type (WT) GST-
CT-Cbl relative to single mutants (Y700F, Y731F, and Y774F)
and a triple mutant (TM) in which Y700, Y731, and Y774 were
mutated to phenylalanine, as illustrated in Fig. 2A.
Fig. 2B and E shows that the SH1 domain of Syk phos-
phorylated each of the single mutants comparably to WT,
while phosphorylation of the TM was substantially reduced
(Fig. 2B, upper panel, top two bands), suggesting that Syk
phosphorylates all three tyrosines with similar ability. Auto-
phosphorylated Syk is shown in each lane except the non-
phosphorylated control, which was incubated without ATP.
The degradation products of the CT-Cbl proteins are phos-
phorylated as well and comigrate with the Syk SH1 domain
(upper panel, lower bands). The lower panel, which represents
total CT-Cbl protein present, was used to normalize for
quantiﬁcation of phosphotyrosine levels (Fig. 2E).
In contrast to Syk, phosphorylation by Fyn was not equal
between the single mutants (Fig. 2C and E). In the Fyn assays,
phosphorylation of Y731F was reduced relative to WT,
Y700F, and Y774F. In fact, Y731F and the TM appeared to
Fig. 1. The SH1 domains of PTKs diﬀerentially phosphorylate c-Cbl domains in vitro. (A) Structure of c-Cbl and schematic of the domains expressed
as GST-fusions and used as substrates for in vitro kinase assays. The c-Cbl domains are designated as NT-Cbl, RF-Cbl, PR-Cbl, and CT-Cbl. Y,
tyrosine; TKB, tyrosine kinase binding; RING, ring ﬁnger; UBA, ubiquitination site; LZ, leucine zipper; 700/731/774, SH2 docking sites. The
migration sites of the GST-Cbl fusions and the autophosphorylated SH1 domains are indicated to the left. Top panel: phosphotyrosine immunoblot
(apTyr); bottom panel: GST immunoblot (aGST). Numbers to the right of the panels indicate molecular weight (kDa). (B) Syk SH1 assay. (C) Fyn
SH1 assay. (D) Abl SH1 assay.
Table 1
Comparison of c-Cbl phosphotyrosine patterns generated by the SH1
domains of Syk, Fyn, and Abl
NT-Cbl RF-Cbl PR-Cbl CT-Cbl
Syk + + + ++
Fyn + ++
Abl ++
The ability of each kinase to phosphorylate a given region of c-Cbl
(labeled at the top of the columns) is designated as +, where ++ is a
higher degree of tyrosine phosphorylation. See Fig. 1A for a descrip-
tion of the c-Cbl fragments.
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Fyn prefers Y731 to other tyrosines in the C-terminus of c-Cbl.
The Abl SH1 domain demonstrated yet another pattern of
phosphorylation (Fig. 2D and E). We anticipated that Abl
would phosphorylate Y700 and Y774 based on previous
studies [1,5,15]. Mutation of Y700 signiﬁcantly reduced the
phosphorylation of CT-Cbl, similar to the levels of phos-
phorylation of the TM. Altering Y731 or Y774 had no obviouseﬀect. The selection of Y700 by Abl is in agreement with recent
data generated by mass spectrometry in which c-Cbl was found
to be phosphorylated at Y700 in Bcr-Abl-expressing cells [16].
Thus, our assay is validated by two independent studies of Abl
speciﬁcity for c-Cbl in vivo.
Fig. 2E summarizes the results of all in vitro kinase assays
using the CT-Cbl proteins, all of which were repeated more
than three times. We consistently observed that the SH1 do-
main of Syk is capable of phosphorylating Y700, Y731, and
Y774 of c-Cbl. The Fyn SH1 domain prefers Y731, while the
Abl SH1 domain prefers Y700. Thus, the three SH1 domains
tested demonstrated distinct preferences for individual tyro-
sines that belong to SH2 recognition motifs of c-Cbl.3.2. Binding of the CrkL SH2 domain to c-Cbl indicates the
sites of c-Cbl phosphorylation
If SH1 domains of PTKs diﬀerentially phosphorylate c-Cbl,
then binding of SH2 domains to their respective phosphoty-
rosine recognition motifs in c-Cbl should reﬂect the predicted
Fig. 2. The SH1 domains of PTKs discriminate between individual tyrosines in the C-terminus of c-Cbl. (A) Schematic of WT and tyrosine (Y) to
phenylalanine (F) mutants of GST-CT-Cbl, which starts with amino acid 541 and ends with 906, as shown. TM, triple mutant; non-P, non-phos-
phorylated. For Syk (B), Fyn (C), and Abl (D) SH1 assays, top panel: phosphotyrosine immunoblot (a-pTyr) and bottom panel: c-Cbl immunoblot
(a-Cbl). Numbers to the left of the panels (B–D) indicate molecular weight (kDa). (E) Average phosphorylation determined from three or more
experiments, shown as % of WT. Black bars: Syk reactions, gray: Fyn, white: Abl. The phosphotyrosine levels were adjusted for loading diﬀerences.
Error bars indicate standard error of the mean.
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tested using gel-overlay assays. Puriﬁed GST-CT-Cbl and the
four tyrosines to phenylalanine mutants were phosphorylated
in vitro by Syk, Fyn, or Abl, separated by gel electrophoresis,
transferred to PVDF membranes, and incubated with the pu-
riﬁed SH2 domain of CrkL. When Syk was used as the kinase
(Fig. 3A), the CrkL SH2 domain readily bound to phosphor-
ylated WT CT-Cbl. Y700 and Y774 of c-Cbl belong to known
recognition motifs for the CrkL SH2 domain and, as pre-
dicted, binding of the CrkL SH2 to Y700F and Y774F CT-Cbl
was reduced relative to WT and Y731F. Binding of CrkL to
the TM was completely abolished, reﬂecting the absence of
both CrkL binding sites. The CrkL SH2 did not bind GST
alone or the non-phosphorylated WT control, indicating that
the interaction is dependent on phosphotyrosine. Fig. 3A also
shows equal loading of the GST-CT-Cbl proteins (middle
panel) and that the phosphotyrosine levels of each protein
were as expected (bottom panel). The pattern of CrkL SH2
binding to the CT-Cbl proteins was consistent in three exper-
iments, as illustrated graphically in Fig. 3D.
The binding pattern of the CrkL SH2 domain to the CT-Cbl
proteins phosphorylated by Fyn was consistent with the
phosphorylation pattern detected by immunoblotting. We had
observed low levels of phosphorylation of Y700 and Y774 by
Fyn relative to Y731 (Fig. 2C) and, therefore, expected some
degree of CrkL binding to WT. Binding to WT (Fig. 3B and
D) conﬁrmed that Fyn has some activity toward Y700 andY774. The activity of Fyn towards Y700 and Y774, however,
was minimal. Mutation of either site alone was enough to
abolish binding by CrkL, consistent with our previous obser-
vation that Fyn has more activity towards Y731 than Y700 or
Y774. Surprisingly, binding to Y731F was consistently higher
than WT, suggesting that Y700 and Y774 were more heavily
phosphorylated when Y731 was absent, allowing more CrkL
binding. It is possible that in our system, using excess kinase,
Fyn directed more activity toward Y700 and Y774 because its
preferred site, Y731, was absent.
When Abl was used to phosphorylate the CT-Cbl proteins, a
third pattern of CrkL SH2 binding was generated (Fig. 3C).
Because we had observed that Abl preferentially phosphory-
lates Y700, we anticipated that most of the CrkL SH2 binding
would occur at Y700 of CT-Cbl. In support of this, the CrkL
SH2 domain failed to bind Y700F CT-Cbl. Binding of the
CrkL SH2 domain to Y774F was slightly reduced (Fig. 3C and
D). The small reduction in binding of CrkL to Y774F suggests
that there was enough phosphorylation of Y774 by Abl, albeit
undetectable by phosphotyrosine immunoblotting (Figs. 2D
and 3C), to mediate some of the interaction. Fig. 3D graphi-
cally represents all three Abl experiments and supports our
conclusion that the Abl SH1 preferentially targets Y700 for
phosphorylation.
In summary, we observed that when the Syk SH1 domain
phosphorylates CT-Cbl, the CrkL SH2 domain readily binds
both Y700 and Y774, but not other sites. Fyn was able to
Fig. 3. Binding of the CrkL SH2 domain to phosphorylated CT-Cbl. CrkL-SH2 gel-overlay assays. GST alone or GST-CT-Cbl proteins were
phosphorylated in vitro by the SH1 domain of Syk (A), Fyn (B), or Abl (C). Top panel: overlay, detected by anti-Flag (a-Flag) immunoblot. Middle
panel: anti-Cbl (a-Cbl) immunoblot. Bottom panel: anti-phosphotyrosine (a-pTyr) immunoblot. Substrates include GST alone (no binding detected,
data not shown) and the CT-Cbl proteins listed above top panel. Non-P, non-phosphorylated WT (no ATP in reaction). Numbers to the left of panel
(A–C) indicate molecular weight (kDa). (D) Average binding determined from three or more experiments, shown as % of WT. Black bars: Syk
reactions, gray: Fyn, white: Abl. Binding intensity was adjusted for loading diﬀerences. Error bars indicate standard error of the mean.
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interaction was weak, reﬂecting Fyn’s selectivity for Y731 over
the CrkL SH2 binding sites. When Y731 is not present, Fyn
can shift its activity towards Y700 and Y774, as suggested by
the increase in binding of the CrkL SH2 to Y731F. In contrast
to Fyn and Syk, phosphorylation by the Abl SH1 limits CrkL
SH2 binding primarily to Y700 of CT-Cbl.
3.3. Binding of the p85 (PI3-K) SH2 domains to c-Cbl
indicates the sites of c-Cbl phosphorylation
Similar to the CrkL scenario, we reasoned that if the SH1
domains of Syk, Fyn, and Abl diﬀerentially phosphorylated
c-Cbl, the binding of the p85 subunit of PI3-K to CT-Cbl
should also reﬂect the phosphorylation patterns of the ki-
nases. Y731 of c-Cbl belongs to a recognition motif (YxxM)
for the p85 subunit of PI3-K [2]. We ﬁrst tested p85N+C,
containing both the amino and carboxy-terminal SH2 do-
mains of p85, for direct interaction with CT-Cbl proteins.
Fig. 4A and D shows that when the Syk SH1 domain
phosphorylated the CT-Cbl proteins, p85N+C bound to
WT, Y700F, and Y774F with similar aﬃnity. Binding to the
TM was abolished while some interaction occurred with
Y731F, suggesting that p85N+C can bind to phosphoY700
or Y774 in addition to Y731.
The binding pattern of p85N+C to the CT-Cbl proteins
phosphorylated by Fyn was identical to the binding pattern
generated by Syk. Fig. 4B shows that the strength of the in-
teraction, with each of the CT-Cbl proteins was equivalent
with the exception of Y731F, which showed a substantial re-
duction in binding, and the TM, which failed to bind p85N+C
altogether. The reduction in binding to Y731F was expectedbased on our observation that the Fyn SH1 preferentially
phosphorylates Y731. The complete loss of interaction with
the TM is consistent with our ﬁndings from the Syk assays in
which p85N+C failed to interact with the TM. Again, the fact
that multiple mutations cause additional loss of interaction
supports the concept that p85N+C can associate with Y700
and/or Y774, in addition to Y731.
An alternative binding-site on CT-Cbl for p85N+C was
conﬁrmed when Abl was used to phosphorylate the CT-Cbl
proteins. Because Abl primarily phosphorylates Y700,
binding of p85N+C to Y700F should be absent if Y700
mediates the interaction. Consistent with this assumption,
Fig. 4C and D shows that binding of p85N+C to Y700F
was almost completely abrogated relative to WT. Binding to
Y731F and Y774F was also reduced, although not dra-
matically. The binding pattern of p85N+C to the Abl-
phosphorylated CT-Cbl proteins supports our conclusion
that Abl preferentially phosphorylates Y700 of c-Cbl and
that the SH2 domains of p85 can bind non-predicted sites
in addition to Y731.
Y700 and Y774 belong to a YxxP motif and are not,
therefore, predicted recognition sites for the p85 SH2 domains.
Because p85 has two SH2 domains, we asked whether the
ability to interact with phosphoY700 and Y774 could be as-
cribed to one particular SH2 domain of p85. Fig. 5A and D
shows that p85-N had a reduced ability to bind Y700F and
Y774F, when phosphorylated by Syk. Binding to Y731F was
severely reduced. Based on these results and the observation
that Syk phosphorylates all three tyrosines with similar eﬃ-
ciency, it appears that p85-N is capable of binding to phos-
phoY700 and Y774 in addition to Y731. We were unable to
Fig. 5. Binding of p85-N to phosphorylated CT-Cbl. Gel-overlay assays with the amino-terminal SH2 domain of the p85 subunit of PI3-K. GST
alone or GST-CT-Cbl proteins were phosphorylated in vitro by the SH1 domain of Syk (A), Fyn (B), or Abl (C). Top panel: overlay, detected by
anti-p85 immunoblot (a-p85). Middle panel: anti-Cbl immunoblot (a-Cbl). Bottom panel: anti-phosphotyrosine immunoblot (a-pTyr). Substrates
include GST alone (no binding detected, data not shown) and the CT-Cbl proteins listed above top panel. Non-P, non-phosphorylated WT (no ATP
in reaction). Numbers to the left of panels (A–C) indicate molecular weight (kDa). (D) Average binding determined from three or more experiments,
with the exception of Syk (represented by two experiments), shown as % of WT. Black bars: Syk reactions, gray: Fyn, white: Abl. Binding intensity
was adjusted for loading diﬀerences. Error bars indicate standard error of the mean.
Fig. 4. Binding of p85-N+C to phosphorylated CT-Cbl. Gel overlays using both SH2 domains of the p85 subunit of PI3-K. GST alone or GST-CT-
Cbl proteins were phosphorylated in vitro by the SH1 domain of Syk (A), Fyn (B), or Abl (C). Top panel: overlay, detected by anti-p85 immunoblot
(a-p85). Middle panel: anti-Cbl immunoblot (a-Cbl). Bottom panel: anti-phosphotyrosine immunoblot (a-pTyr). Substrates include GST alone (no
binding detected, data not shown) and the CT-Cbl proteins listed above top panel. Non-P, non-phosphorylated WT (no ATP in reaction). Numbers
to the left of panels (A–C) indicate molecular weight (kDa). (D) Average binding determined from three or more experiments, shown as % of WT.
Black bars: Syk reactions, gray: Fyn, white: Abl. Binding intensity was adjusted for loading diﬀerences. Error bars indicate standard error of the
mean.
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generate suﬃcient amounts of the puriﬁed protein.
When Fyn was used to phosphorylate the CT-Cbl proteins, a
similar pattern was produced. The p85-N protein failed to bindY731F while binding to Y700F and Y774F was reduced
(Fig. 5B and D), providing further evidence that p85-N can
bind at Y700 and Y774 in addition to Y731. Although the Fyn
SH1 generates a phosphorylation pattern distinct from the Syk
A.H. Grossmann et al. / FEBS Letters 577 (2004) 555–562 561SH1 (Fig. 2B vs. 2C), we learned from the CrkL SH2 overlays
that Fyn phosphorylates Y700 and Y774 to some degree in our
system, even though Y731 is the preferred site. Therefore, the
reduction in binding of p85-N to Y700F and Y774F was not
unexpected for the Fyn-mediated reactions.
Conﬁrmation that p85-N can interact with phosphoY700
and Y774 of c-Cbl came from experiments with the Abl SH1
domain. When Abl was used to phosphorylate the CT-Cbl
proteins, p85-N bound to WT, Y731F, and Y774F but failed
to bind Y700F (Fig. 5C and D). Binding to Y774F was re-
duced but not as severely as Y700F. This binding pattern of
p85-N indicates phosphorylation of Y700 and Y774 by the Abl
SH1 domain, with Y700 being the favored site.
In summary, the SH2 domains of the p85 subunit of PI3
kinase directly interact in vitro with Y731 of c-Cbl when
phosphorylated by Syk and Fyn. Syk also readily phospho-
rylates Y700 and Y774, providing additional docking sites for
p85. When Abl drives the interaction between Cbl and p85, the
binding not only occurs mostly at Y700 but also at Y774. The
ability of p85 to interact with phosphoY700 and Y774 of c-Cbl
is mediated, at least in part, by the amino-terminal SH2 do-
main of p85.4. Discussion
The mechanism by which PTKs achieve speciﬁc signaling
outcomes involves adaptor domains, which guide PTKs to
their substrates [17]. The role of SH1 domains in selective
signaling, however, has been questioned [17] despite evidence
suggesting that PTKs selectively phosphorylate sites within
their targets [5,15,16,18]. In Abl-expressing cells, for example,
Y700 has been reported as a primary site of phosphorylation
on ectopically expressed and endogenous c-Cbl [5,16], while
Crk appears to be primarily phosphorylated at Y221 [18]. Both
sites form the start of a YxxP motif that has been identiﬁed,
using peptide substrates, as the consensus phosphorylation site
for Abl [1,15]. Given that SH1 domains demonstrate prefer-
ences for peptide substrates, we reasoned that the speciﬁcity of
phosphorylation observed in vivo resulted from the selection
of particular tyrosines by the Abl SH1 domain. Broadening
that concept, we hypothesized that SH1 domains, in general,
confer speciﬁcity by selecting distinct tyrosines within their
substrates.
We tested our hypothesis by in vitro kinase assay, using
puriﬁed SH1 domains and c-Cbl domains, and then veriﬁed
our ﬁndings by examining the pattern of phosphotyrosine
mediated interactions between c-Cbl and downstream signal-
ing intermediates that were generated by each PTK. We ob-
served a preference for CT-Cbl, demonstrated by each SH1,
consistent with the pattern of c-Cbl tyrosine phosphorylation
found in vivo [5–7]. The fact that CT-Cbl was the preferred
substrate by each kinase in our in vitro assays is signiﬁcant for
two reasons. First, these data recapitulate the in vivo pattern
of c-Cbl phosphorylation, providing indirect evidence that the
folding state of the GST-Cbl fusion proteins resembles that of
the native c-Cbl protein. Second, it supports data suggesting
that SH1 domains act selectively.
To further analyze the speciﬁcity of SH1 domains for c-Cbl
tyrosines, we asked whether the SH1 domains of Syk, Fyn, and
Abl could discriminate between Y700, Y731, and Y774 of
c-Cbl. Y700 and Y774 are located within the amino acid se-quences EDEYMTP and DDGYDVP, respectively. These se-
quences contain a YxxP motif, similar to the consensus
phosphorylation motif of Abl, IYAxP, identiﬁed by peptide
library screening [1,15]. The YxxP motif also appears in 11 out
of the 21 substrates (not including c-Cbl) listed in the Phos-
pho.ELM database (http://www.phospho.elm.eu.org/) [19] as
Abl phosphorylation sites. Furthermore, Y700 and Y774 were
found to be major sites of c-Cbl phosphorylation in Abl-
transformed cells [5]. We anticipated, therefore, that Abl might
demonstrate selectivity for Y700 and Y774 in our assays. We
observed that the Abl SH1 domain can phosphorylate both
residues but clearly prefers Y700. Interestingly, phosphotyro-
sine mapping of c-Cbl from Bcr-Abl-expressing cells, by mass
spectrometry, detected phosphorylation of Y700 but not Y774
[16]. In essence, the preference we observed for Y700 by the
Abl SH1 is in agreement with several independent reports of
Abl speciﬁcity for c-Cbl in vivo. Again, the results of our assay
reproduce c-Cbl phosphorylation in vivo, validating our assay
and implying that SH1 domains are the ultimate determinants
of phosphorylation sites within their substrates.
A consensus phosphorylation motif has not been reported
for the Fyn SH1 domain. In addition, Phospho.ELM lists only
eight substrates for Fyn other than c-Cbl. None of the other
substrates contain sequences homologous to the c-Cbl sites
phosphorylated by Fyn. It cannot be ruled out, however, that a
common sequence may appear with a larger sample size of
substrates to analyze. The preferred Fyn site that we identiﬁed
in CT-Cbl, Y731, lies within the sequence SCTYEAM. The
EAM sequence downstream of Y731 is similar to the consen-
sus motif identiﬁed for Syk, which includes two negatively
charged amino acids followed by DYE and two uncharged
amino acids [20]. The sequences neighboring Y700 and Y774
(DTEYMTP and DDGYDVP, respectively) conform more
than the Y731 sequences to the predicted Syk motif, with an
adjacent D or E, negatively charged residues upstream, and
uncharged residues downstream. Although the sequences are
similar, they are not identical to the predicted phosphorylation
motif for Syk. Likewise, many of the sequences listed in the
Phospho.ELM database as Syk substrates deviate from the
consensus motifs generated from peptide screens. Out of the 19
non-Cbl substrates listed, four contain YxxP motifs and one
contains an YxxM motif. This variability in Syk substrates is
consistent with our observation that the Syk SH1 domain is
less selective than Abl or Fyn.
Feshchenko et al. [6] reported that coexpression of Syk or
Fyn with c-Cbl in COS cells resulted in equivalent phosphor-
ylation of Y700, Y731, and Y774. While our Syk data are
concurrent with those of Feshchenko et al., our Fyn data are
not. This discrepancy may well be due to the diﬀerences in
techniques used. We used puriﬁed Fyn (SH1), providing ab-
solute certainty that Fyn directly phosphorylates Y731. In
cells, ectopic expression of full-length Fyn could have activated
endogenous PTKs or Fyn may have associated with other
PTKs and brought them to c-Cbl. Our use of puriﬁed proteins
eliminated the potential for confounding eﬀects from addi-
tional PTKs, a problem that exists when using immunopre-
cipitated proteins or in vivo coexpression studies.
The phosphorylation patterns observed with phosphotyro-
sine immunoblotting were conﬁrmed in gel-overlay assays. The
binding pattern of the CrkL SH2 domain, which recognizes
phosphoY700 and phosphoY774, was in agreement with
the predicted phosphorylation pattern of the PTK used. The
562 A.H. Grossmann et al. / FEBS Letters 577 (2004) 555–562binding pattern of the SH2 domains of p85 also reﬂected the
substrate preferences of the SH1 domains. Importantly, the
GST-Cbl proteins were able to bind their respective SH2
partners in a speciﬁc manner, demonstrating again that these
fusion proteins fold in a native manner. Interestingly, the Abl
SH2 domain has been reported to selectively bind an YxxP-like
motif [21], suggesting that there may be similarities in the
substrate recognition properties of SH1 and SH2 domains.
In addition to conﬁrming phosphorylation patterns, we
observed that p85 is not limited to interacting with Y731 of c-
Cbl. Simultaneous binding of both SH2 domains of p85 has
been shown to result in optimal PI3-K activation [22]. Fur-
thermore, c-Cbl has been reported to enhance PI3-K activation
[23,24]. It is possible that c-Cbl engages both SH2 domains of
p85 to facilitate activation of PI3-K.
Our ﬁndings imply that phosphorylation of c-Cbl by mul-
tiple PTKs may be necessary for the viability of downstream
signaling pathways. For instance, the association of c-Cbl with
CIN85 requires phosphorylation of Y700, Y731, and Y774
[8,10]. Diﬀerential phosphorylation of these tyrosines may be a
point of regulation in the endophilin-CIN85-Cbl pathway,
which facilitates EGF and c-Met receptor downregulation [9].
In Fyn and Abl signaling, phosphorylation of c-Cbl would be
incomplete and require additional PTKs to be recruited. In T
lymphocytes, Fyn and Syk are upstream activators of T cell
receptor signaling [25] and associate with and phosphorylate c-
Cbl [26,27] to enable the association of c-Cbl with CrkL and
PI3-K [26]. Fyn may activate PI3-K by phosphorylating Y731
of c-Cbl but would have to rely on its ability to recruit Syk
to c-Cbl [27] in order for the CrkL binding sites to be
phosphorylated.
Similar to Fyn, Abl is known to associate with other PTKs
[28]. In v-Abl transformed ﬁbroblasts, phosphorylation of
Y700, Y731, and Y774 appears to be necessary for c-Cbl to
promote ﬁbronectin deposition, adhesion and spreading
[29,30]. While Y700, and possibly Y774, could be targets of
Abl, phosphorylation of Y731 is likely to be carried out by a
distinct PTK. Thus, diﬀerential phosphorylation of c-Cbl may
allow for the integration of diverse upstream signals.
In summary, we have shown that SH1 domains of Abl, Syk,
and Fyn diﬀerentially phosphorylate the protein c-Cbl. Fyn and
Abl demonstrated striking preferences for particular sites, while
Syk appeared to have less speciﬁcity. The site(s) of phosphor-
ylation selected by each SH1 domain could be loosely predicted
by the consensus motifs generated from phosphopeptide library
analysis. More importantly, our data are in agreement with
reports of c-Cbl phosphorylation patterns in vivo, validating
our assay and providing indirect evidence that the c-Cbl sub-
strates we used in vitro were folded in a native conformation.
For example, the c-terminus of Cbl is the primary site of
phosphorylation in vivo [5–7] and our in vitro data are identical.
CT-Cbl was signiﬁcantly more phosphorylated than all other
domains. Second, our in vitro data for Abl reproduced the in
vivo phosphorylation pattern of c-Cbl in Abl-expressing cells.
And third, the CT-Cbl proteins acted like natively folded c-Cbl
in our gel overlay assays by binding their respective SH2 part-
ners in a phosphotyrosine speciﬁc manner. Because the SH1
domains were able to diﬀerentially phosphorylate natively fol-
ded c-Cbl fragments, we concluded that SH1 domains can be
suﬃcient to confer speciﬁcity when phosphorylating a targetprotein. Our data support a model that SH1 domains determine
sites of phosphorylation once a PTK has been targeted to its
substrate by adaptor domain interactions. Selection of speciﬁc
tyrosines within a substrate could conceivably limit the ability
of a PTK to fully trigger downstream pathways, requiring ad-
ditional kinases to contribute, but would ensure that a given
pathway is consistently activated.
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